P0036 The presence of clustered circulating tumour cells (CTCS) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer

2014 ◽  
Vol 50 ◽  
pp. e18-e19 ◽  
Author(s):  
R. Divella ◽  
A. Mazzocca ◽  
A. Daniele ◽  
A. Bellizzi ◽  
E. Savino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Aggressive Phenotype ◽  
Circulating Cytokines

scholarly journals Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer

2021 ◽  
Vol 22 (4) ◽  
pp. 2067
Author(s):  
Rhynelle S. Dmello ◽  
Sarah Q. To ◽  
Ashwini L. Chand
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Liver Metastasis ◽  
Metastatic Colorectal Cancer ◽  
Tumour Microenvironment ◽  
Tumour Cells ◽  
Cellular Interactions ◽  
Circulating Tumour Cells ◽  
Therapeutic Targeting ◽  
Colorectal Cancer Patients

Liver metastasis is the primary contributor to the death of patients with colorectal cancer. Despite the overall success of current treatments including targeted therapy, chemotherapy, and immunotherapy combinations in colorectal cancer patients, the prognosis of patients with liver metastasis remains poor. Recent studies have highlighted the importance of the tumour microenvironment and the crosstalk within that determines the fate of circulating tumour cells in distant organs. Understanding the interactions between liver resident cells and tumour cells colonising the liver opens new therapeutic windows for the successful treatment of metastatic colorectal cancer. Here we discuss critical cellular interactions within the tumour microenvironment in primary tumours and in liver metastases that highlight potential therapeutic targets. We also discuss recent therapeutic advances for the treatment of metastatic colorectal cancer.

scholarly journals Molecular markers in circulating tumour cells from metastatic colorectal cancer patients

2010 ◽  
Vol 14 (8) ◽  
pp. 2073-2077 ◽  
Author(s):  
Paola Gazzaniga ◽  
Angela Gradilone ◽  
Arianna Petracca ◽  
Chiara Nicolazzo ◽  
Cristina Raimondi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Molecular Markers ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Colorectal Cancer Patients

scholarly journals A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

2012 ◽  
Vol 16 (10) ◽  
pp. 2342-2349 ◽  
Author(s):  
Jorge Barbazán ◽  
María Vieito ◽  
Alicia Abalo ◽  
Lorena Alonso-Alconada ◽  
Laura Muinelo-Romay ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Logistic Model ◽  
Tumour Cells ◽  
Circulating Tumour Cells

The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer

2014 ◽  
Vol 25 (11) ◽  
pp. 1531-1541 ◽  
Author(s):  
Rosa Divella ◽  
Antonella Daniele ◽  
Ines Abbate ◽  
Antonia Bellizzi ◽  
Eufemia Savino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Aggressive Phenotype ◽  
Circulating Cytokines

scholarly journals Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study

2015 ◽  
Vol 112 (8) ◽  
pp. 1306-1313 ◽  
Author(s):  
U Bork ◽  
N N Rahbari ◽  
S Schölch ◽  
C Reissfelder ◽  
C Kahlert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prospective Study ◽  
Metastatic Colorectal Cancer ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
A Prospective Study

scholarly journals A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer

2018 ◽  
Vol 14 (2) ◽  
pp. 137-146 ◽  
Author(s):  
Wen-Chi Chou ◽  
Min-Hsien Wu ◽  
Pei-Hung Chang ◽  
Hung-Chih Hsu ◽  
Gwo-jyh Chang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Prognostic Model ◽  
Survival Outcome ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Model Based

scholarly journals PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

2020 ◽  
Vol 21 (18) ◽  
pp. 6907
Author(s):  
Lucrezia Raimondi ◽  
Filippo Maria Raimondi ◽  
Laura Di Benedetto ◽  
Giuseppe Cimino ◽  
Gian Paolo Spinelli
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tyrosine Kinases ◽  
Progression Free Survival ◽  
Predictive Biomarker ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Multikinase Inhibitor ◽  
The Third ◽  
Third Line

Regorafenib, targeting a broad range of receptor tyrosine kinases (RTKs), is an oral multikinase inhibitor which improves the progression-free survival (PFS) and overall survival (OS) of patients diagnosed with chemorefractory metastatic colorectal cancer (mCRC), making an immunosuppressive tumour microenvironment. The correlation between PD-1/PD-L1 expression and RTKs inhibition has been studied in several tumour types but has not been analyzed extensively in mCRC in the era of regorafenib. In this study, using liquid biopsy, we evaluated the opportunity to reveal if PD-L1 expression on circulating tumour cells (CTCs) could serve as a predictive biomarker of response and clinical benefit in patients treated with regorafenib as the third line of treatment. We analyzed a cohort of forty chemorefractory metastatic colorectal cancer patients, of whom twenty-six KRAS mutated, treated with regorafenib, all as the third line of treatment. Blood samples were collected from patients prior to treatment and longitudinally four and eight weeks after initiation of therapy. CTCs were identified using multiparametric flow cytometry; therefore, PD-L1 expression was evaluated. Objective responses were defined following the RECIST criteria v.1.1. Moreover, focusing on peripheral blood biomarkers, we found that high platelet-to-lymphocyte ratio (PLR) was an independent prognostic indicator of poor OS. For the first time, our study showed the usefulness of sequential assessments of CTCs as a non-invasive real-time biopsy to evaluate PD-L1 expression in patients diagnosed with mCRC and treated with regorafenib. Our analysis suggests that by assessing PD-L1 expression on CTCs, we could predict who will benefit from regorafenib, offering highly individualized treatment plans.

Sign in / Sign up

Export Citation Format

Share Document